Nitric oxide regulates the 26S proteasome in vascular smooth muscle cells

It is well established that nitric oxide (NO) inhibits vascular smooth muscle cell (VSMC) proliferation by modulating cell cycle proteins. The 26S proteasome is integral to protein degradation and tightly regulates cell cycle proteins. Therefore, we hypothesized that NO directly inhibits the activity of the 26S proteasome. The three enzymatic activities (chymotrypsin-like, trypsin-like and caspase-like) of the 26S proteasome were examined in VSMC. At baseline, caspase-like activity was approximately 3.5-fold greater than chymotrypsin- and trypsin-like activities. The NO donor S-nitroso-N-acetylpenicillamine (SNAP) significantly inhibited all three catalytically active sites in a time- and concentration-dependent manner (P < 0.05). Caspase-like activity was inhibited to a greater degree (77.2% P < 0.05). cGMP and cAMP analogs and inhibitors had no statistically significant effect on basal or NO-mediated inhibition of proteasome activity. Dithiothreitol, a reducing agent, prevented and reversed the NO-mediated inhibition of the 26S proteasome. Nitroso-cysteine analysis following S-nitrosoglutathione exposure revealed that the 20S catalytic core of the 26S proteasome contains 10 cysteines which were S-nitrosylated by NO. Evaluation of 26S proteasome subunit protein expression revealed differential regulation of the α and β subunits in VSMC following exposure to NO. Finally, immunohistochemical analysis of subunit expression revealed distinct intracellular localization of the 26S proteasomal subunits at baseline and confirmed upregulation of distinct subunits following NO exposure. In conclusion, NO reversibly inhibits the catalytic activity of the 26S proteasome through S-nitrosylation and differentially regulates proteasomal subunit expression. This may be one mechanism by which NO exerts its effects on the cell cycle and inhibits cellular proliferation in the vasculature.     

NO induced apoptosis of vascular smooth muscle cells accompanied by ceramide increase

We have shown previously that nitric-oxide (NO) can induce apoptosis of vascular smooth muscle cells (VSMCs) and that the NO-induced apoptosis is accompanied by an increase in arachidonic acid release via cytoplasmic Ca(2+)-dependent phospholipase A(2) (cPLA(2)). We have evidence that during NO-induced apoptosis there is an increase in ceramide synthesis. The use of inhibitors of ceramide synthesis, namely, fumonisin B1 and desipramine, which block ceramide synthase and sphingomyelinase, respectively revealed that the ceramide was produced via the sphingomyelinase pathway. Inhibition of acid sphingomyelinase by desipramine was shown to inhibit NO-induced apoptosis while fumonisin B1 failed to inhibit this process. C(2)-ceramide could induce apoptosis in cultured VSMCs. Apoptosis in smooth muscle cells was accompanied by the increased activity of DNA fragmentation factor-40 and the secretion of cathepsin D from the cells. In this study, ceramide appears to function as a mediator of apoptosis.     

Oxidant-induced arachidonic acid release and impairment of fatty acid acylation in vascular smooth muscle cells

Oxidativedamage, which plays a major role in the early stages ofatherosclerosis, is associated with arachidonic acid (AA) release invascular smooth muscle cells (VSMC) as in other cell types. In thisstudy,H₂O₂was used to investigate mechanisms of AA release from VSMC on oxidativestress. Cell treatment with H₂O₂inhibited AA incorporation in an inverse relationship to prolongedH₂O₂-inducedAA release. Identical kinetics of inhibition of AA incorporation and AArelease were observed after cell treatment withAlF₄, a process not involvingphospholipase A₂(PLA₂) activation as recentlydescribed (A. Cane, M. Breton, G. Béréziat, and O. Colard.Biochem. Pharmacol. 53: 327-337, 1997). AA release was not specific, since oleic acid also increased inthe extracellular medium of cells treated withH₂O₂or AlF₄ as measured by gaschromatography-mass spectrometry. In contrast, AA and oleic acid cellcontent decreased after cell treatment. Oleoyl and arachidonoylacyl-CoA synthases and acyltransferases, assayed using a cell-freesystem, were not significantly modified. In contrast, a goodcorrelation was observed between decreases in AA acylation and cell ATPcontent. The decrease in ATP content is only partially accounted for bymitochondrial damage as assayed by rhodamine 123 assay. We concludethat oxidant-induced arachidonate release results from impairment offatty acid esterification and that ATP availability is probablyresponsible for free AA accumulation on oxidative stress by preventingits reesterification and/or transmembranetransport.

     

cPLA2 activator peptide, PLAP, increases arachidonic acid release and apoptosis of vascular smooth muscle cells

Apoptosis of vascular smooth muscle cells (VSMCs) has recently drawn a lot of interest in various laboratories due to its importance in atherogenesis. We have shown previously that nitric-oxide (NO) can induce apoptosis of VSMCs and that the NO-induced apoptosis is accompanied by an increase in arachidonic acid release via cytoplasmic Ca(2+)-dependent phospholipase A(2) (cPLA(2)). We have demonstrated here that NO-induced activation of cPLA(2) leading to increased arachidonic acid release can be mimicked via direct activation of cPLA(2) with a cPLA(2) activator peptide, PLAP. The PLAP induced arachidonic acid release and apoptosis is inhibitable by a cPLA(2)-specific inhibitor, AACOCF(3), indicating the direct involvement of cPLA(2). In this study, activation of cPLA(2) appears to be preceded by activation and binding by PLAP indicating that the cPLA(2) functions are mediated via PLAP.     

Endogenous arachidonic acid metabolism by cultured arterial smooth muscle cells

Cultured aortic smooth muscle cells originated from healthy and atherosclerotic rabbits produce prostaglandins (namely prostacyclin) at a basal state. Prostaglandin secretion is dramatically reduced in atherosclerotic cells. This impairment was not correlated with any alteration of acyl hydrolase activities and probably involved a decrease of cyclooxygenase activities.     

Nitric oxide modulates Gi-protein expression and adenylyl cyclase signaling in vascular smooth muscle cells

We have previously shown that treatment of rats with the nitric oxide (NO) synthase inhibitor N6-nitro-L-arginine methyl ester for 4 weeks resulted in the augmentation of blood pressure and enhanced levels of Gialpha proteins. The present studies were undertaken to investigate if NO can modulate the expression of Gi proteins and associated adenylyl cyclase signaling. A10 vascular smooth muscle cells (VSMC) and primary cultured cells from aorta of Sprague-Dawley rats were used for these studies. The cells were treated with S-nitroso-N-acetylpenicillamine (SNAP) or sodium nitroprusside (SNP) for 24 h and the expression of Gialpha proteins was determined by immunobloting techniques. Adenylyl cyclase activity was determined by measuring [32P]cAMP formation for [alpha-32P]ATP. Treatment of cells with SNAP (100 microM) or SNP (0.5 mM) decreased the expression of Gialpha-2 and Gialpha-3 by about 25-40% without affecting the levels of Gsalpha proteins. The decreased expression of Gialpha proteins was reflected in decreased Gi functions (receptor-independent and -dependent) as demonstrated by decreased or attenuated forskolin-stimulated adenylyl cyclase activity by GTPgammaS and inhibition of adenylyl cyclase activity by angiotensin II and C-ANP4-23, a ring-deleted analog of atrial natriuretic peptide (ANP) that specifically interacts with natriuretic peptide receptor-C (NPR-C) in SNAP-treated cells. The SNAP-induced decreased expression of Gialpha-2 and Gialpha-3 proteins was not blocked by 1H[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one, an inhibitor of soluble guanylyl cyclase, or KT5823, an inhibitor of protein kinase G, but was restored toward control levels by uric acid, a scavenger of peroxynitrite and Mn(111)tetralis (benzoic acid porphyrin) MnTBAP, a peroxynitrite scavenger and a superoxide dismutase mimetic agent that inhibits the production of peroxynitrite, suggesting that NO-mediated decreased expression of Gialpha protein was cGMP-independent and may be attributed to increased levels of peroxynitrite. In addition, Gsalpha-mediated stimulation of adenylyl cyclase by GTPgammaS, isoproterenol, and forskolin was significantly augmented in SNAP-treated cells. These results indicate that NO decreased the expression of Gialpha protein and associated functions in VSMC by cGMP-independent mechanisms. From these studies, it can be suggested that NO-induced decreased levels of Gi proteins and resultant increased levels of cAMP may be an additional mechanism through which NO regulates blood pressure.     

Superoxide is responsible for apoptosis in rat vascular smooth muscle cells induced by alpha-tocopheryl hemisuccinate

We investigated the mechanism of cell toxicity of alpha-tocopheryl hemisuccinate (TS). TS concentration- and time-dependently induced the lactate dehydrogenase release and DNA fragmentation of rat vascular smooth muscle cells (VSMC). Exogenous addition of superoxide dismutase, but not catalase, significantly inhibited the cell toxicity of TS. The NADPH-dependent oxidase activity of VSMC was stimulated by TS treatment. The cell toxicity of TS was inhibited by NADPH oxidase inhibitor 4-(2-aminoethyl)-benzenesulfonyl fluoride. Consequently, TS-induced apoptosis of VSMC was suggested to be caused by exogenous O(2)(-) generated via the oxidase system activated with TS.     

Succinobucol induces apoptosis in vascular smooth muscle cells

Probucol inhibits the proliferation of vascular smooth muscle cells in vitro and in vivo, and the drug reduces intimal hyperplasia and atherosclerosis in animals via induction of heme oxygenase-1 (HO-1). Because the succinyl ester of probucol, succinobucol, recently failed as an antiatherogenic drug in humans, we investigated its effects on smooth muscle cell proliferation. Succinobucol and probucol induced HO-1 and decreased cell proliferation in rat aortic smooth muscle cells. However, whereas inhibition of HO-1 reversed the antiproliferative effects of probucol, this was not observed with succinobucol. Instead, succinobucol but not probucol induced caspase activity and apoptosis, and it increased mitochondrial oxidation of hydroethidine to ethidium, suggestive of the participation of H(2)O(2) and cytochrome c. Also, succinobucol but not probucol converted cytochrome c into a peroxidase in the presence of H(2)O(2), and succinobucol-induced apoptosis was decreased in cells that lacked cytochrome c or a functional mitochondrial complex II. In addition, succinobucol increased apoptosis of vascular smooth muscle cells in vivo after balloon angioplasty-mediated vascular injury. Our results suggest that succinobucol induces apoptosis via a pathway involving mitochondrial complex II, H(2)O(2), and cytochrome c. These unexpected results are discussed in light of the failure of succinobucol as an antiatherogenic drug in humans.     

Goniothalamin induces apoptosis in vascular smooth muscle cells

Restenosis represents a major impediment to the success of coronary angioplasty. Abnormal proliferation of vascular smooth muscle cells (VSMCs) has been shown to be an important process in the pathogenesis of restenosis. A number of agents, particularly rapamycin and paclitaxel, have been shown to impact on this process. This study was carried out to determine the mechanisms of cytotoxicity of goniothalamin (GN) on VSMCs. Results from MTT cytotoxicity assay showed that the IC(50) for GN was 4.4 microg/ml (22 microM), which was lower compared to the clinically used rapamycin (IC(50) of 25 microg/ml [27.346 microM]). This was achieved primarily via apoptosis where up to 25.83 +/- 0.44% of apoptotic cells were detected after 72 h treatment with GN. In addition, GN demonstrated similar effects as rapamycin in inhibiting VSMCs proliferation using bromodeoxyuridine (BrdU) cell proliferation assay after 72 h treatment at IC(50) concentration (p > 0.05). In order to understand the mechanisms of GN, DNA damage detection using comet assay was determined at 2h post-treatment with GN. Our results showed that there was a concentration-dependent increase in DNA damage in VSMCs prior to cytotoxicity. Moreover, GN effects were comparable to rapamycin. In conclusion, our data show that GN initially induces DNA damage which subsequently leads to cytotoxicity primarily via apoptosis in VSMCs.     

Regulation of Akt by arachidonic acid and phosphoinositide 3-kinase in angiotensin II-stimulated vascular smooth muscle cells

Angiotensin (Ang) II stimulates cytosolic phospholipase A2(cPLA(2))-dependent release of arachidonic acid (ArAc) in vascular smooth muscle cells (VSMC). ArAc release and production of reactive oxygen species (ROS) lead to the activation of downstream kinases resulting in VSMC growth. To determine the role of Akt in this pathway, we used VSMC to link Ang II-induced ArAc release and ROS production to the activation of Akt and VSMC growth. We observed that Ang II, ArAc, or H(2)O(2) increased Akt activation. The Akt inhibitor SH6 blocked Ang II-, ArAc-, or H(2)O(2)-induced Akt activation, as did inhibition of phosphoinositide 3-kinase (PI(3)K). Inhibition of cPLA(2) blocked Ang II effects, while the ROS scavenger NaC decreased Ang II- and ArAc-induced Akt activation. Inhibition of Akt blocked the (3)H-thymidine incorporation induced by all three agonists. Thus, Ang II-induced ArAc release and ROS production leads to the PI(3)K-dependant activation of Akt and VSMC growth.     

Phorbol ester dissociates endothelin-stimulated phosphoinositide hydrolysis and arachidonic acid release in vascular smooth muscle cells

Endothelin-stimulated [3H]-inositol phosphate formation and [3H]-arachidonic acid release were measured in cultured vascular smooth muscle cells from rabbit renal artery. Both responses were partially inhibited by pretreatment with pertussis toxin, indicating the involvement of pertussis toxin-sensitive guanine nucleotide binding regulatory proteins in the coupling processes. Pretreatment with the phorbol ester PMA inhibited endothelin-stimulated [3H]-inositol phosphate formation, but potentiated endothelin-stimulated [3H]-arachidonic acid release, suggesting that these two coupling processes occur in a parallel and independent manner in vascular smooth muscle cells.     

EGF-induced adipose tissue mesothelial cells undergo functional vascular smooth muscle differentiation

Recent studies suggested that the post-natal mesothelium retain differentiative potential of the embryonic mesothelium, which generates fibroblasts and vascular smooth muscle cells (VSMCs), in developing coelomic organs via epithelial-to-mesenchymal transition (EMT). Whether adult mesothelial cells (MCs) are able to give rise to functional VSMCs in vitro and which are the factors and mechanisms directing this process remain largely unknown. Here, we isolated adipose tissue MCs (ATMCs) from adult mice, and demonstrated that ATMCs cultured in a serum-containing media supplemented with epidermal growth factor (EGF) efficiently increased both their proliferation and EMT above levels found in only serum-containing media cultures. EGF-induced ATMCs gained phosphorylation of the EGF receptor and activated simultaneously ILK/Erk1/2, PI3K/Akt and Smad2/3-dependent pathways. Sequential subculture onto collagen-I surface efficiently improved their vasculogenic EMT towards cells featuring VSMCs (α-SMA, calponin, caldesmon, SM22α, desmin, SM-MHC, smoothelin-B and PDGFR-β) that could actively contract in response to receptor and non-receptor-mediated vasoactive agonists. Overall, our results indentify EGF signalling as a robust vasculogenic inductive pathway for ATMCs, leading to their transdifferentiation into functional VSMC-like cells.Stem cell-based pro-angiogenic therapies hold great promise to revascularize ischemic tissues in patients with acute myocardial infarction or chronic limb ischemia.^{1, 2, 3, 4} The plasticity of pluripotent embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells allows their easy derivation towards Isl-1⁺ multipotent cardiovascular progenitors that clonally give rise to cardiomyocytes, vascular smooth muscle cells (VSMCs) and endothelial cells,^{5, 6} the major cell types of cardiovascular tissues. Safety concerns, differentiation efficiency, overcoming immune rejection and the inherent tumourigenicity of pluripotent stem cells, however, remains a major issue hindering their clinical application^{7, 8} and will require the validation of efficient gating strategies allowing the purification of ESC- and iPS-derived multipotent cardiovascular progenitors for future use in cardiovascular regenerative medicine.Adult tissues retain a small subset of resident undifferentiated stem cells that can self-renew asymmetrically to generate committed progenitors for the replenishment of the different cellular phenotypes that are lost during normal tissue turnover. Although adult stem cells display restricted lineage differentiation potential and limited proliferative capacities, their lack of tumourigenicity has attracted great attention for establishing safe cell-based regenerative therapies.^{9, 10, 11} Stromal mesenchymal stem cells (MSCs) are multipotent stem cells residing around the vasculature of virtually all organs and vascularized tissues.^{12, 13} It is now widely accepted that MSCs display significant immunosuppressive activity¹⁴ and angiogenic potential and improve long-term neovascularization outcomes of ischemic tissues⁴ mainly through their paracrine secretion of pro-angiogenic factors such as bFGF, EGF, PDGF-BB, VEGF and TGFβ1, rather by a direct incorporation into the neovasculature as it was initially thought.¹⁵ Despite the extensive focus on the pro-angiogenic potential of MSCs, the identification of new sources of adult stem cells with neovascularization potential remains a goal that is under research.The adult mesothelium is a squamous epithelial layer of mesoderm origin lining coelomic cavities and the visceral organs housed within. Cumulating evidence indicates that the adult mesothelium is a rich reservoir of mesothelial cells (MCs) with pro-vasculogenic potential.^{16, 17, 18, 19} The adult mesothelium was thought to be a ‘quiescent tissue'' solely endowed with physiological functions such as to maintain serosal integrity and inflammation and to secrete large amounts of ‘lubricants'' to favour the correct sliding of opposite serosal layers (i.e., for the beating heart). A recent report, however, set a breakthrough in this concept showing that the post-natal mesothelium remains a source of progenitor cells giving rise to fibroblasts and VSMCs in visceral organs of healthy mice.¹⁹ Furthermore, it was also shown that MCs give rise to hepatic stellate cells and myofibroblasts in injured liver.²⁰ Another striking example recently demonstrates that the mesothelium is a source for adipocytes that often physically attach to the visceral organs.²¹The findings that adult MCs of human and rodent origin can recapitulate in vitro an epithelial-to-mesenchymal transition (EMT) and acquire SMCs markers in response to provasculogenic and morphogenic growth factors (i.e, TGF-β1, PDGF-BB, bFGF and EGF)^{10, 16, 17, 22, 23, 24} led to the hypothesis that adult MCs may retain the differentiative potential of embryonic MCs, which were shown to generate fibroblasts and VSMCs in the developing heart, lung, gut and liver.^{25, 26, 27, 28, 29, 30} We recently pushed onward this concept by demonstrating that adult mouse uterine MCs (UtMCs) subjected to provasculogenic culture undergo EMT towards progenitors that can subsequently acquire properties of differentiated VSMCs upon sequential subculture.¹⁸ Despite these exiting findings uncovering an unexpected mesodermal plasticity and vasculogenic potential for adult MCs, the factors and mechanisms inducing and directing their vasculogenic differentiation towards a functional VSMCs phenotype remain largely unknown.The visceral adipose tissue (AT) is composed of several adipose depots, including mesenteric, epididymal white AT and perirenal depots. In humans, the major visceral AT depot corresponds to the greater omentum, a large fold of the peritoneum.³¹ In mice, the major visceral AT depots are attached to the uterus and ovaries in females and the epididyme and testes in males. Its tremendous remodelling capacity allows its rapid adaptation to an excess food intake through adipocyte hyperplasia, a process that is closely coupled with neovascularization.^{32, 33}The expansion and neovascularization potential of the visceral AT is likely to indicate that its surrounding mesothelium retain strong vasculogenic potential, a particularity that should make this tissue a valuable source of cells for cardiovascular regenerative therapy.Herein, we show that a gentle trypsinization of the adult mouse uterine AT can efficiently and reliably detach a highly enriched population of AT mesothelial cells (ATMCs) from its covering mesothelium. ATMCs cultured in a high glucose-based media (BMe) with serum and 50 ng/ml of epidermal growth factor (EGF; termed BMe+50EGF) could actively proliferate and acquire EMT, progenitor and cardiovascular developmental markers. Upon repeated subculture onto collagen type I-coated surface, ATMCs drastically reduced their proliferation rate while improving in turn their transdifferentiation towards fibroblastic cells displaying molecular and functional characteristics of differentiated VSMCs.     

Regulatory effects of eicosanoids on thymidine uptake by vascular smooth muscle cells of rats

To define the roles of eicosanoids in vascular smooth muscle cells (VSMC) growth, we examined the effects of exogenous eicosanoids on (3H)thymidine uptake by cultured VSMC of Wistar rats. Stable prostacyclin (PGI2) analog, OP-41483, significantly decreased the incorporation of (3H)thymidine into deoxyribonucleic acid (DNA) of VSMC in a dose dependent manner from 10(-8) to 10(-4) M. Prostaglandin E2 (PGE2) and PGD2 ranging from 10(-8) to 10(-4) M also dose-dependently decreased the (3H)thymidine uptake by VSMC. In contrast, stable thromboxane A2 analog, STA2, significantly increased the incorporation of (3H)thymidine into DNA in a dose dependent manner from 10(-8) to 10(-4) M. The dose response curve of STA2 was shifted toward a lowered response when 10(-5) M PGI2 analog, PGE2 or PGD2 was added in the culture medium. Thus, it is indicated that vasodepressor eicosanoids decrease the proliferation of VSMC, whereas vasoconstrictor TXA2 enhances the VSMC growth. Vascular smooth muscle cells possibly autoregulate the cell proliferation through the eicosanoids generation.     

Induction of apoptosis in vascular smooth muscle cells by mechanical stretch

We studied the response of porcine vascular smooth muscle cells (PVSMCs) to cyclic sinusoidal stretch at a frequency of 1 Hz. Cyclic stretch with an area change of 25% caused an increase in PVSMC apoptosis, which was accompanied by sustained activation of c-Jun NH(2)-terminal kinases (JNK) and the mitogen-activated protein kinase p38. Cyclic stretch with an area change of 7% had no such effect. Infection of PVSMCs with recombinant adenoviruses expressing constitutively active forms of upstream molecules that activate JNK and p38 also led to apoptosis. The simultaneous blockade of both JNK and p38 pathways with adenovirus-mediated expression of dominant-negative mutants of c-Jun and p38 caused a significant decrease (to 1/2) of the apoptosis induced by 25% cyclic stretch. The 25% stretch also caused sustained clustering of tumor necrosis factor-alpha (TNF-alpha) receptor-1 and its association with TNF-alpha receptor-associated factor-2 (TRAF-2). Overexpressing the wild-type TRAF-2 in PVSMCs caused an increase in apoptosis. In contrast, the expression of a dominant-negative mutant of TRAF-2 attenuated stretch-induced apoptois. These results support the hypothesis that circumferential overload under hypertensive conditions induces a clustering of death receptors that cause vascular smooth muscle cell apoptosis.     

Nitric oxide synthase induction,cGMP elevation,and biopterin synthesis in vascular smooth muscle cells stimulated with interleukin-1beta in hypoxia

In cultured rat vascular smooth muscle cells (VSMC), inducible nitric oxide synthase (iNOS) expression evoked by interleukin-1beta (IL-1beta) or tumor necrosis factor-alpha was greatly enhanced in hypoxia (2% O(2)), compared to in normoxia. In contrast, iNOS induction by interferon-gamma, lipopolysaccharide or their combination was barely influenced by hypoxia. These results indicate that iNOS induction is regulated by hypoxia in different manners, depending on the stimuli in VSMC. Nitric oxide (NO) production in response to stimulation with interferon-gamma plus lipopolysaccharide was significantly decreased in hypoxia, due to a decrease in the concentration of O(2) as a substrate. In contrast, the level of NO production in hypoxia was almost the same as that in normoxia when the cells were stimulated by IL-1beta. In addition, cGMP increased in response to IL-1beta in hypoxia to a level comparable to that in normoxia. Thus, it seems that the IL-1beta-induced expression of iNOS is up-regulated in hypoxia to compensate for a decrease in the enzyme activity due to the lower availability of O(2) as a substrate, and consequently a sufficient amount of NO is produced to elevate cGMP to an adequate level. In addition, the IL-1beta-induced synthesis of tetrahydrobiopterin, a cofactor for iNOS, was also greatly stimulated by hypoxia in VSMC.     

UV-C照射诱导体外血管平滑肌细胞凋亡模型的建立

应用常规细胞培养超净台紫外消毒灯（２２０Ｗ,２２０Ｖ,５０Ｈｚ）发射的ＵＶ－Ｃ波段的紫外光源（２５４ｎｍ）,垂直照射距离其１０ｃｍ处的大鼠主动脉平滑肌细胞,发现经照射后细胞出现典型的凋亡形态学改变,如细胞变圆,染色质浓缩,细胞膜出泡,出现凋亡小体等;细胞面积,核面积及核／胞面积比均显著降低;且提取细胞ＤＮＡ的琼脂糖凝胶电泳呈现梯状图谱。从形态学和生化指标方面证明了ＵＶ－Ｃ照射可诱导体外血管ＳＭＣｓ     

Involvement of the mitogen-activated protein kinase cascade in peroxynitrite-mediated arachidonic acid release in vascular smooth muscle cells

Eicosanoid production is reduced when the nitric oxide (NO·) pathway is inhibited or when the inducible NO synthase gene is deleted, indicating that the NO· and arachidonic acid pathways are linked. We hypothesized that peroxynitrite, formed by the reaction of NO· and superoxide anion, may cause signaling events leading to arachidonic acid release and subsequent eicosanoid generation. Western blot analysis of rat arterial smooth muscle cells demonstrated that peroxynitrite (100–500 µM) and 3-morpholinosydnonimine (SIN-1; 200 µM) stimulate phosphorylation of extracellular signal-regulated kinase (ERK), p38, and cytosolic phospholipase A₂ (cPLA₂). We found that peroxynitrite-induced arachidonic acid release was completely abrogated by the mitogen-activated protein/ERK kinase (MEK) inhibitor U0126 and by calcium chelators. With the p38 inhibitor SB-20219, we demonstrated that peroxynitrite-induced p38 phosphorylation led to minor arachidonic acid release, whereas U0126 completely blocked p38 phosphorylation. Addition of arachidonic acid caused p38 phosphorylation, suggesting that arachidonic acid or its metabolites are responsible for p38 activation. KN-93, a specific inhibitor of Ca²⁺/calmodulin-dependent kinase II (CaMKII), revealed no role for this kinase in peroxynitrite-induced arachidonic acid release in our cell system. Together, these results show that in response to peroxynitrite the cell initiates the MEK/ERK cascade leading to cPLA₂ activation and arachidonic acid release. Thus studies investigating the role of the NO· pathway on eicosanoid production must consider the contribution of signaling pathways initiated by reactive nitrogen species. These findings may provide evidence for a new role of peroxynitrite as an important reactive nitrogen species in vascular disease. reactive nitrogen species; prostaglandin H₂ synthase; extracellular signal-regulated kinase; p38; cytosolic phospholipase A₂     

Superoxide determines nitric oxide uptake rate by vascular smooth muscle cells

Nitric oxide (NO) is generated in endothelial cells, which diffuses to vascular smooth muscle cells (SMCs), activates soluble guanylyl cyclase, and leads to blood vessel dilation. However, this scenario does not explain how SMCs are capable of competing with erythrocytic hemoglobin for NO in vivo. Here, we have developed a competition experiment to determine the NO uptake rate by SMCs and demonstrated that the SMC-NO uptake rate is positively dependent on intracellular superoxide levels. In addition, the superoxide-elicited NO influx is able to enhance cGMP production in SMCs. Our findings imply that vascular SMCs, in vivo, may use superoxide to compete with erythrocytic hemoglobin for NO and obtain the NO bioactivity.